PLRX

Pliant is a pre-revenue clinical-stage biopharma whose entire value rests on one early asset, PLN-101095, an oral αvβ8/αvβ1 inhibitor for solid tumors. The fundamentals offer nothing to anchor to: revenue has gone to $0.00 for two straight years (FY2024 and FY2025), the FY2025 net loss was -$149M, operating cash flow was -$128M, and accumulated deficit sits at -$859M. ROE is -82.4%. The 'improvements' the data shows (net loss YoY +29%, R&D -35.5%, total assets -43.3%) are not a turnaround — they reflect a company shrinking and conserving cash after the collapse of its prior lead program, consistent with the 10-K's reference to INTEGRIS-PSC results and a pivot to oncology.

The defining problem is solvency, not story. Cash & equivalents are just $45.4M against a $128M annual operating burn. Even counting the full $196M current-asset base (the rest in short-term investments), runway is roughly 18 months — and the company has explicitly launched an 'accelerated' Phase 1b that will consume cash, with first-patient enrollment only this quarter and interim data not expected until 2027. That timeline guarantees a dilutive capital raise well before any value-inflection readout. With 61.9M shares at $1.15, the equity is ~$71M — a fraction of the $181M book — which is the market correctly pricing in burn plus near-certain dilution rather than a hidden bargain.